Less acid + less bleeding = better outcomes and more money!
Enns
Robert
R
Department of Medicine, Division of Gastroenterology, St Paul's Hospital, University of British Columbia, Vancouver, Canada. renns@interchange.ubc.ca
D053799:2-Pyridinylmethylsulfinylbenzimidazoles; D000897:Anti-Ulcer Agents / Q000008:administration & dosage / Q000191:economics; D001562:Benzimidazoles / Q000008:administration & dosage / Q000191:economics; D002986:Clinical Trials as Topic; D003362:Cost-Benefit Analysis; D004791:Enzyme Inhibitors / Q000008:administration & dosage* / Q000191:economics; D005744:Gastric Acid / Q000378:metabolism*; D005773:Gastroscopy / Q000191:economics; D017048:Health Care Costs; D006801:Humans; D007262:Infusions, Intravenous; D009853:Omeprazole / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000191:economics; D000077402:Pantoprazole; D010438:Peptic Ulcer Hemorrhage / Q000191:economics / Q000378:metabolism / Q000628:therapy*; D054328:Proton Pump Inhibitors; D013276:Stomach Ulcer / Q000191:economics / Q000378:metabolism / Q000628:therapy*; D013454:Sulfoxides / Q000008:administration & dosage / Q000191:economics; D016896:Treatment Outcome
D053799:2-Pyridinylmethylsulfinylbenzimidazoles; D000897:Anti-Ulcer Agents; D001562:Benzimidazoles; D004791:Enzyme Inhibitors; D054328:Proton Pump Inhibitors; D013454:Sulfoxides; D000077402:Pantoprazole; D009853:Omeprazole